Investing in AI: Benefits, Regulatory Challenges

Update: 2024-11-07

Description

No discussion regarding the future is complete unless AI is incorporated.

In this episode, Konstantina Katcheves of Teva Pharmaceuticals and Sanskriti Thakur of TOWER Capital Group provide their insights on the impact of not only the benefits of the technology but the regulatory challenges and uncertainty surrounding AI.

Host

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpace

Guests

Konstantina Katcheves, Senior Vice President, Innovative Medicines Global Business Development and Acquisitions, Teva Pharmaceuticals

Sanskriti Thakur, Chairwoman, TOWER Capital

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Navigating Patient Journeys with Tom Whitehead

2025-02-1317:29

New M&A Action, BMS’ Ongoing Cost Cuts and the Insatiable Demand for Weight Loss Drugs

2025-02-1211:39

RFK Jr. Advances, Q4 Earnings Roll Out and a Non-Opioid Pain Drug Hits the Market

2025-02-0516:37

The Patient's Perspective with Tom Whitehead

2025-01-3012:53

RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More

2025-01-2917:29

Trump Takes Over, Wegovy Still Trails Zepbound and BioSpace Recaps JPM

2025-01-2220:02

Bonus: Q4 2024 Job Market Update

2025-01-2110:27

A Conversation with Peter Marks: Insights into GenScript Biotech Forum 2025

2025-01-1618:45

Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More

2025-01-1512:13

A Conversation with Peter Marks and Tom Whitehead: Insights into GenScript Biotech Forum 2025 (Teaser)

2025-01-1006:40

NextGen Class of 2025, M&A Uptick Predicted Heading Into JPM, FDA Decisions to Watch

2025-01-0814:20

Trials and Capital: Women’s Health and APAC's Healthcare Revolution

2025-01-0216:53

Analysis vs Beliefs, CEO Challenges, GLP-1 Investments

2024-12-1924:09

Biopharma’s Manufacturing Push and Other 2024 Trends

2024-12-1813:25

Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More

2024-12-1110:00

Previous Investment Patterns Set to Repeat in 2025

2024-12-0523:07

Biopharma’s Shopping Spree, Applied Crashes on Rejection, Skysona’s Safety Concerns, More

2024-12-0412:03

BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More

2024-11-2718:46

51%: The Untapped Market

2024-11-2113:12

RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More

2024-11-2015:07

00:00

Investing in AI: Benefits, Regulatory Challenges

#box-pro-ellipsis-173971965156839{-webkit-line-clamp:2;}Investing in AI: Benefits, Regulatory Challenges

Investing in AI: Benefits, Regulatory Challenges

BioSpace

Investing in AI: Benefits, Regulatory Challenges